NAD+ Therapy Clinics in 2026: IV NAD+, NR, NMN, Safety, and Evidence

If there’s one treatment that has come to define modern longevity medicine, it’s NAD+ therapy. Walk into any longevity clinic in 2026 — from Next Health in Los Angeles to Progevita in Valencia to Chi Longevity in Bangkok — and NAD+ is on the menu. It’s one of the most visible interventions across our clinic directory, offered at 11 of 55 clinics in our database.

But NAD+ therapy isn’t a single treatment. It’s a category with fundamentally different delivery methods, dosing protocols, evidence levels, safety issues, and price points. The practical choices now include direct IV NAD+ infusions, IV nicotinamide riboside (NR), oral nicotinamide mononucleotide (NMN), oral NR, and lower-cost vitamin B3 approaches.

This guide breaks down the science behind both approaches, what the clinical evidence actually shows, what they cost, and how to think about the choice.

Medical note: NAD+ protocols are not FDA-approved for anti-aging or longevity. This guide is informational, not medical advice. If you have cancer history, unexplained symptoms, pregnancy or lactation, liver or kidney disease, arrhythmia, cardiac symptoms, or complex medications, treat NAD+ as a physician-review decision rather than a wellness add-on.

June 2026 Update: The Evidence Got More Serious, Not More Certain

A 2025 expert review in Nature Aging, circulated widely in March 2026, summarizes NAD+-related clinical translation across aging and neurodegenerative disease. Its message is useful for buyers because it is not promotional: NAD+ biology is important, but dose, route, long-term safety, tissue-specific effects, and individual response remain unresolved.¹

The review’s strongest patient takeaway is that NAD+ is a serious research field, not that every commercial infusion is proven. A clinic can be right that NAD+ participates in cellular energy, DNA repair, and stress-response pathways, while still being wrong if it implies that raising a blood NAD+ marker proves slower aging, dementia prevention, or longer life.

Two additional 2026 updates matter for clinic shopping:

• The FDA warned compounders that food-grade NAD+ ingredients are not automatically suitable for sterile injectable drugs and reported adverse events after NAD+ injectables, including severe chills, shaking, vomiting, and fatigue requiring medical treatment.²
• A 2026 retrospective pilot comparing commercial IV NAD+ with IV NR found shorter average infusion times and fewer moderate-to-severe infusion symptoms in the IV NR group, but the study was preliminary, real-world, short-term evidence and did not prove durable healthspan benefits.³

The buyer question has therefore changed. It is no longer “does the clinic offer NAD+?” It is “which molecule, which route, what sterile-drug quality control, what medical oversight, and what outcome are we actually tracking?”

What Is NAD+ and Why Does It Matter?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every cell in the human body. It plays a central role in cellular energy metabolism (converting food to ATP), DNA repair (activating PARP enzymes), gene expression regulation (activating sirtuins), and cellular signaling pathways involved in aging.⁴

The connection to aging is direct: NAD+ levels decline with age. Studies in mice have shown that by middle age, NAD+ concentrations in key tissues drop to approximately 50% of youthful levels.⁵ This decline is associated with mitochondrial dysfunction, impaired DNA repair, increased inflammation, and metabolic deterioration — hallmarks of the aging process.

The therapeutic hypothesis is straightforward: if declining NAD+ drives aging phenotypes, then restoring NAD+ levels should slow or reverse those phenotypes. The question is how best to do that.

The Main Approaches: IV NAD+, IV NR, and Oral Precursors

IV NAD+ Infusions

Intravenous NAD+ delivers the molecule directly into the bloodstream, bypassing the digestive system entirely. A typical clinic protocol involves:

• Dose: 250–1,000 mg per session (varies by clinic and protocol)
• Duration: 2–6 hours per infusion (NAD+ must be administered slowly to avoid side effects)
• Frequency: 1–4 sessions per treatment course; some protocols recommend quarterly maintenance
• Setting: Clinical — requires IV access and medical supervision
• Common side effects: Nausea, chest tightness, cramping during infusion (rate-dependent); these typically resolve by slowing the drip rate

The primary advantage of IV NAD+ is immediate bloodstream exposure. The disadvantages are practical and clinical: each session requires IV access, slow administration, sterile-drug quality control, medical supervision, and significantly higher cost. Direct NAD+ also appears to produce more infusion discomfort than IV NR in early real-world data, though the evidence remains preliminary.³

IV Nicotinamide Riboside

Some clinics and med-spa operators now offer IV NR rather than direct IV NAD+. NR is a precursor that cells convert into NAD+. The commercial argument is shorter infusion time and potentially better tolerability.

The best current evidence is still early. In a 2026 retrospective pilot, clients received four consecutive days of 500 mg IV NAD+ or IV NR with 30-day follow-up. Average infusion time was 97 minutes for NAD+ IV and 37 minutes for NR IV. NAD+ recipients reported moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusion; NR recipients reported milder tingling and cramping. Symptoms resolved after infusion, and longer-term effectiveness beyond 30 days was not established.³

That makes IV NR interesting, not proven. Ask the same questions you would ask for direct IV NAD+: supplier, dose, sterility, clinician oversight, adverse-event plan, and why IV delivery is being recommended over oral NR.

Oral Precursors: NMN and NR

Rather than delivering NAD+ directly, oral supplements provide precursor molecules that the body converts to NAD+ through enzymatic pathways:

Nicotinamide Mononucleotide (NMN)

• Converted to NAD+ via the enzyme NMNAT
• Typical dosing: 250–1,000 mg/day
• Available as capsules, sublingual tablets, or powder
• Regulatory status: FDA classified NMN as a “new dietary ingredient” in late 2022, temporarily restricting its sale as a supplement. As of 2026, NMN remains in regulatory limbo in the US, though widely available internationally and through compounding pharmacies.

Nicotinamide Riboside (NR)

• Converted to NMN (then NAD+) via the enzyme NRK
• Typical dosing: 300–1,000 mg/day
• Marketed under the brand Niagen® (ChromaDex)
• More established regulatory path — recognized as GRAS (Generally Recognized As Safe) by the FDA
• Available over the counter in the US

Both precursors have demonstrated the ability to raise NAD+ levels in human blood cells. The critical questions are: by how much, for how long, in which tissues, and with what clinical benefit?

What the Evidence Shows

Animal Studies: Strong and Consistent

The preclinical case for NAD+ restoration is compelling. Across multiple mouse models, NMN and NR supplementation has been shown to:

• Restore age-related NAD+ decline in muscle, liver, and brain tissue⁵
• Improve mitochondrial function and oxidative metabolism⁶
• Enhance insulin sensitivity and glucose tolerance⁷
• Protect against age-related cognitive decline⁸
• Extend healthspan (though not definitively lifespan) in various mouse models

These results have been replicated across dozens of independent laboratories, making NAD+ precursors among the most robust interventions in preclinical aging research. However, mice are not humans, and extrapolation requires caution.

Human Studies: Emerging but Incomplete

Human clinical data is accumulating but remains at an earlier stage:

NMN Human Trials:

• A 2022 randomized controlled trial (n=30, 250 mg/day for 12 weeks) showed NMN increased blood NAD+ metabolites and improved muscle insulin sensitivity in postmenopausal women with prediabetes.⁹
• A 2024 meta-analysis of NMN and NR human trials concluded that both precursors reliably increase blood NAD+ levels, but evidence for downstream clinical benefits (improved physical performance, metabolic markers, cognitive function) remains mixed and study sizes are small.¹⁰

NR Human Trials:

• The CHROMAVITA trial (n=140) demonstrated that NR (1,000 mg/day) safely increased NAD+ in blood by approximately 60% over 8 weeks in healthy middle-aged adults.
• A 2023 trial showed NR reduced markers of systemic inflammation (IL-6, IL-2) in heart failure patients — suggesting potential cardiovascular benefit.¹¹

IV NAD+ Human Data:

• Published clinical trial data for IV NAD+ specifically is limited. Most IV NAD+ evidence comes from addiction medicine protocols (particularly the BR+ NAD® protocol), observational reports from longevity clinics, and case series rather than randomized controlled trials.
• No large-scale RCTs comparing IV NAD+ to oral precursors in a longevity context have been published as of early 2026.

The Honest Assessment

The animal data is strong. The human data for oral precursors is promising but not yet definitive. The human data for IV NAD+ specifically is thin, and the 2026 IV NAD+ versus IV NR pilot is better read as tolerability evidence than effectiveness proof. This is a treatment where the biological rationale is sound, the preclinical evidence is robust, but the clinical proof in humans is still being built.

This doesn’t mean NAD+ therapy is ineffective — it means we’re in the evidence-accumulation phase. Patients opting for NAD+ in 2026 are making a bet that the preclinical promise will translate to clinical benefit. That bet may well pay off. But intellectual honesty requires acknowledging the gap between mouse studies and human proof.

Stanford’s Tony Wyss-Coray made this point sharply in a recent Huberman Lab episode: “On NMN, he’s pragmatic: raising a molecule in blood is not the same as shifting frailty, dementia, or mortality.” Peter Attia echoes this in Outlive — the question isn’t whether NAD+ levels go up (they do), but whether that translates to the outcomes that actually matter: function, resilience, and lifespan.

IV NAD+, IV NR, NMN, and Oral NR: Head-to-Head

Factor	IV NAD+	IV NR	Oral NMN	Oral NR
Route	Sterile infusion	Sterile infusion	Capsule, powder, sublingual	Capsule or powder
Typical dose	250-1,000 mg/session	Often 500 mg/session in commercial protocols	250-1,000 mg/day	300-1,000 mg/day
Session time	Often 2-6 hours; 97 min average in one pilot	37 min average in one pilot	Seconds	Seconds
Common side effects	Nausea, cramping, chest pressure, increased heart rate during infusion	Tingling or mild cramping in early pilot data	Generally well-tolerated in short trials	Generally well-tolerated in short trials
Clinical trial data	Limited for longevity outcomes	Very early for IV use	Several small human trials	More human data than NMN
Regulatory issue	Sterile compounding quality matters; not approved for longevity	Same sterile-drug questions	U.S. supplement status remains contested	Supplement safety pathways do not equal drug approval
Cost signal	Highest	High	Low to moderate	Low to moderate
Best use case	Monitored clinic protocol with clear reason for IV route	Monitored clinic protocol if supplier/sterility and rationale are clear	At-home precursor approach where legal/available	At-home precursor with more established human evidence

When IV Makes Sense

IV NAD+ may be preferable when:

• You want rapid NAD+ restoration (acute protocol over days rather than gradual oral supplementation over weeks)
• You’re combining NAD+ with other IV treatments at a clinic (many longevity clinics bundle NAD+ with other infusions)
• You have GI issues that may impair oral absorption
• You’re doing an intensive residential longevity program where IV delivery is convenient

When Oral Makes Sense

Oral NMN or NR may be preferable when:

• You want ongoing daily NAD+ support without regular clinic visits
• Cost is a consideration — oral is 10–50x cheaper per month than IV sessions
• You prefer the safety profile of treatments with more published clinical trial data
• You want regulatory clarity (NR in particular has an established FDA safety pathway)

The Combination Approach

An increasingly common protocol among longevity physicians: IV NAD+ during an initial clinic visit or annual assessment (a “loading phase”), followed by daily oral NMN or NR for maintenance between clinic visits. This combines the immediate impact of IV delivery with the convenience and cost-effectiveness of oral supplementation.

Cost Breakdown

IV NAD+ at Clinics

Pricing varies significantly by clinic and geography:

• US clinics (Next Health, 10X Health, Forever Health): $750–$2,500 per session
• European clinics (Progevita, SHA Wellness Clinic, The Longevity Lab): €500–€1,500 per session
• Asian/Middle East clinics (Chi Longevity, Biocure, AEON Clinic): $400–$1,200 per session

A typical 4-session treatment course costs $3,000–$10,000 in the US, less in Europe and Asia. Some residential programs (Progevita, Chi Longevity) include NAD+ IV as part of all-inclusive program pricing.

Oral Supplements

• NMN (250 mg/day): $50–$100/month (varies by brand and source)
• NMN (500 mg/day): $80–$150/month
• NR/Niagen® (300 mg/day): $40–$60/month
• NR/Niagen® (600 mg/day): $60–$100/month

Over a year, daily oral supplementation costs $500–$1,800 — roughly equivalent to a single IV session.

Which Clinics Offer NAD+ IV Therapy?

Of the 55 clinics in our directory, 11 currently offer NAD+ IV therapy:

Europe:

• Progevita — Valencia, Spain (included in residential programs)
• SHA Wellness Clinic — Alfaz del Pi, Spain
• The Longevity Lab — London, UK

United States:

• Next Health — Los Angeles
• Forever Health — Dallas
• 10X Health System — Aventura, FL

Asia & Middle East:

• Chi Longevity — Bangkok, Thailand
• Biocure — Dubai, UAE
• AEON Clinic — Dubai, UAE

Americas:

• LONVIDA — Mexico City
• Eterna Health — Toronto, Canada

Use our clinic comparison tool to filter by NAD+ availability and see side-by-side program details.

How to Compare NAD+ Therapy Clinics

The best NAD+ clinics should sound more cautious than the loudest NAD+ clinics. You are not buying the molecule alone; you are buying route choice, medical screening, sterile-drug discipline, monitoring, and honesty about uncertainty.

Clinic model	Likely NAD+ offer	What to verify	Minimum oversight	Red flag
Walk-in IV drip bar	Direct IV NAD+ or IV NR	Exact molecule, dose, infusion rate, supplier, sterility standard	Clinician screening before first infusion and adverse-event plan on site	”Cellular rejuvenation” claims with no labs or physician review
Longevity clinic	IV NAD+, oral NR/NMN, or combined loading and maintenance	Baseline labs, medication review, contraindications, reassessment date	Physician-designed protocol and follow-up documentation	Bundles NAD+ with peptides or exosomes without evidence tiers
Diagnostics-first clinic	NAD+ only if risk assessment supports it	Whether NAD+ is optional or driven by a proprietary score	Written rationale after diagnostics	Uses a low NAD+ marker as the main sales trigger
Residential program	NAD+ inside a broader recovery or regenerative menu	Whether every guest gets the same protocol or it is individualized	Medical director oversight, nursing protocol, clear stop rules	Treats NAD+ as mandatory package padding

Before paying, request written answers to these questions:

1. Which molecule are you using? Direct NAD+, IV NR, oral NR, NMN, nicotinamide, niacin, or a blend are not interchangeable.
2. Why this route? Ask why IV is recommended instead of oral NR or NMN, especially if the clinic charges premium infusion prices.
3. What dose, rate, frequency, and reassessment date? A credible clinic should state milligrams, infusion duration, planned frequency, and when the protocol is reviewed.
4. Who supplies or compounds the injectable? For IV therapy, ask whether the product is intended and processed for sterile drug use, not merely food-grade or supplement-grade material.²
5. Who supervises the infusion? Ask for the supervising clinician’s credentials and the escalation plan for chest symptoms, severe chills, vomiting, faintness, or arrhythmia-like symptoms.
6. What outcomes are tracked? Energy scores alone are weak. Better follow-up includes symptoms, medication changes, metabolic markers, sleep, exercise tolerance, and adverse effects.
7. What claims will you not make? A medically careful clinic will not claim that NAD+ prevents Alzheimer’s disease, Parkinson’s disease, cancer, or aging itself.

If the clinic cannot answer clearly, the problem is not only evidence. It is governance.

Safety and Regulatory Considerations

IV NAD+ and IV NR: These are sterile injectable products, so supplier quality matters. In 2026, FDA specifically reminded compounders not to use food-grade NAD+ ingredients for sterile drugs without appropriate processing because microbial and endotoxin contamination can harm patients. FDA also reported adverse events after NAD+ injectable drugs, including severe chills, shaking, vomiting, and fatigue requiring medical treatment.² That does not mean every IV NAD+ protocol is unsafe, but it makes supplier verification and adverse-event planning non-negotiable.

Common NAD+ infusion symptoms include nausea, chest pressure, increased heart rate, abdominal cramping, malaise, sweating, and headache. Some symptoms are rate-dependent and may improve when the infusion is slowed. IV NR may be better tolerated than IV NAD+ in early commercial data, but that finding needs confirmation in stronger trials.³

Oral NMN: Well-tolerated in clinical trials at doses up to 1,250 mg/day. No serious adverse events reported in published RCTs. Long-term safety data (>1 year) is limited.

Oral NR: The most safety data of any NAD+ approach. Generally well-tolerated at 1,000 mg/day. Mild GI symptoms (nausea, diarrhea) reported at higher doses. FDA GRAS designation provides an additional safety benchmark.

One theoretical concern that deserves mention: some researchers have raised questions about whether NAD+ restoration could promote the growth of existing (but undetected) tumors, since cancer cells also depend on NAD+ metabolism. As of early 2026, no clinical data supports this concern in humans, but it remains an area of active investigation.¹² This is another reason why comprehensive diagnostics (including cancer screening) before starting NAD+ therapy is a reasonable precaution — and one that full-service longevity clinics are well-positioned to provide.

Do not start IV NAD+ or IV NR without physician review if you are pregnant or lactating, have active cancer or recent cancer treatment, unexplained weight loss, fever, new neurologic symptoms, chest symptoms, arrhythmia, significant liver or kidney disease, immune compromise, or a history of severe infusion reactions.

The Bottom Line

NAD+ therapy in 2026 sits at an interesting inflection point. The biological rationale is sound, the animal data is strong, and human trials are increasingly supportive — particularly for oral NR, which has the most clinical evidence. IV NAD+ offers immediate bloodstream exposure but with thinner outcome evidence, much higher cost, and sterile-compounding safety questions that buyers should now ask about directly.

If you want the strongest evidence-based approach: Oral NR (Niagen®) at 300–1,000 mg/day. More human trial data, FDA GRAS status, and 10–50x lower cost than IV.

If you want the most medically supervised route: IV infusion at a longevity clinic, ideally combined with comprehensive diagnostics, supplier transparency, sterile-drug quality control, and a written adverse-event plan.

If you want both: An initial IV loading phase during a clinic visit (or as part of a residential program at a clinic like Progevita or Chi Longevity), followed by daily oral NMN or NR for maintenance.

The field is moving fast. Several large-scale human RCTs for both NMN and NR are underway or reporting results in 2026. The evidence base a year from now will be substantially stronger than it is today. For patients considering NAD+ therapy, the honest advice is: the biology is promising, the early human data is encouraging, but we’re not yet at the “definitive proof” stage. Proceed with informed optimism and written due diligence.

---

Frequently Asked Questions

Is NAD+ therapy FDA-approved?

No. NAD+ therapy is not FDA-approved for anti-aging or longevity. IV NAD+ is administered off-label at longevity clinics. Oral NR may have supplement safety pathways such as GRAS, but that is not drug approval. NMN’s regulatory status in the US remains uncertain.

How quickly does IV NAD+ work?

Most patients report subjective effects (improved energy, mental clarity) within hours to days of an IV infusion. Measurable changes in blood NAD+ levels are immediate. Whether these acute effects translate to long-term health benefits is not yet established in large clinical trials.

Is IV NR safer than IV NAD+?

Possibly, but the evidence is early. A 2026 retrospective pilot found shorter infusion times and fewer moderate-to-severe symptoms with IV NR than IV NAD+ in a commercial setting. It did not prove superior long-term effectiveness, and both routes still require sterile injectable quality controls and medical oversight.

What should I ask before booking IV NAD+?

Ask for the exact molecule, dose, infusion rate, frequency, supplier or compounder, sterile-drug quality standard, supervising clinician, contraindication review, adverse-event plan, reassessment date, and written claim boundary. If the clinic cannot provide these, do not treat it as precision medicine.

Can I take NMN and NR together?

Some longevity practitioners recommend combining NMN and NR, reasoning that they enter the NAD+ synthesis pathway at different points. However, no clinical trial has demonstrated that combining both is more effective than either alone. Most researchers recommend one or the other.

How long should I take NAD+ supplements?

There is no established protocol for duration. Most longevity physicians recommend ongoing daily supplementation based on the logic that NAD+ decline is continuous with age. Some recommend cycling (3 months on, 1 month off). Discuss with your physician.

Are there natural ways to boost NAD+?

Yes. Exercise (particularly high-intensity interval training) has been shown to increase NAD+ levels. Caloric restriction and time-restricted eating also upregulate NAD+ synthesis pathways. These lifestyle interventions are free, evidence-based, and complementary to supplementation.

---

This guide reflects published evidence and regulatory updates checked on June 12, 2026 and is for informational purposes only. Consult a physician before starting any NAD+ protocol.

Primary source: Nature Aging: Emerging strategies, applications and challenges of targeting NAD+ in the clinic (Source: Nature Aging, 2025).

Footnotes

1. Zhang, J. et al., “Emerging strategies, applications and challenges of targeting NAD+ in the clinic,” Nature Aging 5, 1704-1731 (2025). doi:10.1038/s43587-025-00947-6; PubMed PMID:40926126. ↩

2. U.S. Food and Drug Administration, “FDA reminds compounders to use ingredients suitable for sterile compounding” (2026). FDA. ↩ ↩² ↩³

3. Hewlings, S. et al., “Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting,” Frontiers in Aging (2026). doi:10.3389/fragi.2026.1652582. ↩ ↩² ↩³ ↩⁴

4. Yoshino, J. et al., “NAD+ intermediates: The biology and therapeutic potential of NMN and NR,” Cell Metabolism 27(3), 513–528 (2018). doi:10.1016/j.cmet.2017.11.002 ↩

5. Camacho-Pereira, J. et al., “CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism,” Cell Metabolism 23(6), 1127–1139 (2016). doi:10.1016/j.cmet.2016.05.006 ↩ ↩²

6. Gomes, A.P. et al., “Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging,” Cell 155(7), 1624–1638 (2013). doi:10.1016/j.cell.2013.11.037 ↩

7. Yoshino, J. et al., “Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice,” Cell Metabolism 14(4), 528–536 (2011). doi:10.1016/j.cmet.2011.08.014 ↩

8. Mills, K.F. et al., “Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice,” Cell Metabolism 24(6), 795–806 (2016). doi:10.1016/j.cmet.2016.09.013 ↩

9. Yoshino, M. et al., “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women,” Science 372(6547), 1224–1229 (2021). doi:10.1126/science.abe9985 ↩

10. Reiten, O.K. et al., “Preclinical and clinical evidence of NAD+ precursors in health, disease, and ageing,” Signal Transduction and Targeted Therapy 6, 218 (2021). doi:10.1038/s41392-021-00686-3 ↩

11. Airhart, S.E. et al., “An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers,” PLOS ONE 12(12), e0186459 (2017). doi:10.1371/journal.pone.0186459 ↩

12. Navas, L.E. & Carnero, A., “NAD+ metabolism, stemness, the immune response, and cancer,” Signal Transduction and Targeted Therapy 6, 2 (2021). doi:10.1038/s41392-020-00354-w ↩